Studies in G12C and G12D KRAS-mutant lung cancer mouse models and organoids treated with KRAS inhibitors reveal that tumors invoke a lineage plasticity program to switch from adenocarcinoma to squamous via transcriptomic and epigenomic changes, modulating the response to KRAS inhibition [55]. The gene discussed is KRAS; the disease is lung carcinoma.